Introduction {#Sec1}
============

Ulcerative colitis (UC) is a chronic inflammatory bowel disease with an unpredictable course of relapse and remission \[[@CR1], [@CR2]\]. Inflammation and mucosal damage associated with UC are a consequence of immune dysregulation, including overexpression of proinflammatory cytokines such as tumor necrosis factor (TNF) \[[@CR3]\]. Disease-related immune dysregulation has been associated with genetic polymorphisms, which may differ depending on the population being examined; for example, a recent meta-analysis found that inflammatory bowel disease susceptibility loci in Japanese patients are closely associated with human leukocyte antigen regions \[[@CR4]\]. Japanese patients with UC who have a family history of the disease tend to have an earlier onset and a more severe course of disease \[[@CR5]\].

Adalimumab is a subcutaneously administered, recombinant, fully human, monoclonal antibody directed against TNF. Phase III trials of adalimumab in Western patients with moderately to severely active UC who failed therapy with steroids and/or immunomodulators (including some patients who had previously failed other anti-TNF agents) demonstrated the ability of adalimumab to induce and maintain remission at an induction dose of 160/80 mg (week 0/week 2) and a maintenance dose of 40 mg every other week (EOW) \[[@CR6]--[@CR8]\]. Based on these results, adalimumab was approved in the United States and the European Union for the treatment of adult patients with moderately to severely active UC.

The incidence and prevalence of UC in Japan are lower than in Western countries, though they are rapidly increasing \[[@CR9]\]. The safety and efficacy of adalimumab in the treatment of Crohn's disease (CD) in Japanese patients have been recently demonstrated \[[@CR10]\]. Here, we report the results of a 52-week efficacy and safety trial of adalimumab in anti-TNF--naïve Japanese patients with moderately to severely active UC.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This 52-week, phase II/III, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety, and pharmacokinetics of adalimumab for induction and maintenance therapy in Japanese patients with moderately to severely active UC. The objective of this study was to show the directional similarity of study results compared with Western studies \[[@CR6]--[@CR8]\] using descriptive statistics. The study was conducted at 65 centers in Japan between February 2009 and May 2011. The protocol was approved by the institutional review board of each center, and each patient provided written consent. For patients aged 19 and younger, written consent was also provided by the patient's guardian.

Patient population {#Sec4}
------------------

Japanese patients ≥15 years of age with biopsy-confirmed, moderately to severely active UC (Mayo score \[[@CR11]\] \[a composite of stool frequency, rectal bleeding, physician's global assessment (PGA), and endoscopy subscores\] of 6--12 points and an endoscopy subscore of ≥2) despite concurrent treatment with stable doses of oral corticosteroids (prednisolone equivalent of ≥20 mg/day for ≥2 weeks or 5 to \<20 mg/day for ≥40 days before baseline) and/or immunomodulators (azathioprine ≥50 mg/day or 6-mercaptopurine \[6-MP\] ≥30 mg/day for at least 90 days) were enrolled. If patients were receiving both oral corticosteroids and immunomodulators at baseline, only one of the drugs needed to meet the above criteria. Patients who were previously treated with corticosteroids or immunomodulators during the past 5 years and who, in the judgment of the investigator, had failed to respond or who could not tolerate their treatment were also eligible for enrollment. Patients who had received prior treatment with anti-TNF therapies or other biologic agents were not eligible.

Key exclusion criteria included the following: planned bowel surgery; discontinuation of oral corticosteroids within 2 weeks before baseline; receipt of corticosteroid injection, cyclosporine, tacrolimus, or mycophenolate mofetil within 4 weeks before baseline; receipt of therapeutic enema or suppository, other than required for endoscopy, within 2 weeks before screening endoscopy; receipt of cytapheresis within 56 days of baseline; receipt of total parenteral nutrition during the screening period; receipt of any investigational agent within 4 weeks or 5 half-lives before baseline; or nonstable doses or recent (within 4 weeks) discontinuation of oral aminosalicylates or UC-related antibiotics (e.g., ciprofloxacin, metronidazole). Other reasons for exclusion included the following: current diagnosis of fulminant colitis or toxic megacolon; disease limited to the rectum (ulcerative proctitis); current diagnosis of indeterminate colitis or CD; positive *Clostridium difficile* toxin stool assay result; recent history of infection requiring antimicrobial therapy; evidence of tuberculosis infection by chest X-ray or purified protein derivative skin test; administration of a live vaccine within 90 days before baseline; history of listeria or histoplasmosis, active tuberculosis, human immunodeficiency virus, immunodeficiency syndrome, central nervous system demyelinating disease, or malignancy (except successfully treated, nonmetastatic, cutaneous squamous cell or basal cell carcinoma, or localized carcinoma in situ of the cervix); evidence of colonic dysplasia; history of poorly controlled medical conditions (e.g., uncontrolled diabetes); or known hypersensitivity to excipients of adalimumab.

Treatment administration {#Sec5}
------------------------

Patients were randomly assigned in a 1:1:1 ratio to subcutaneous injections of adalimumab (160 mg at week 0, 80 mg at week 2, and then 40 mg EOW beginning at week 4 \[160/80 arm\], or 80 mg at week 0, 40 mg at week 2, and then 40 mg EOW beginning at week 4 \[80/40 arm\]), or placebo administered by a physician or nurse. The study drug was added to ongoing background therapy for UC (no therapies were washed out). Randomization was based on a centrally designed randomization table. Changes in doses of UC-related concomitant medications other than corticosteroids were not permitted during the study. After the initial 8-week induction period, patients who responded to treatment according to the judgment of the investigator were allowed to taper their corticosteroid dose. Patients with an inadequate response to the study drug (partial Mayo score greater than or equal to that of the baseline score on two consecutive visits at least 14 days apart for patients with a baseline partial Mayo score of 3--7, or partial Mayo score ≥7 on two consecutive visits at least 14 days apart for patients with a baseline partial Mayo score of 8 or 9) or with a flare (partial Mayo score increase of ≥3 compared with the score at the last evaluation before the disease flare on two consecutive visits at least 14 days apart) at or after week 8 were entered into the "rescue arm." Treatment in the "rescue arm" consisted of 4 weeks of blinded adalimumab (either 160 mg initially and 80 mg 2 weeks later for patients in the placebo arm, or 40 mg initially and 2 weeks later for patients in either adalimumab arm) followed by open-label adalimumab 40 mg EOW, with a possibility to escalate to 80 mg EOW in case of inadequate response or disease flare at least 8 weeks later.

Efficacy evaluations {#Sec6}
--------------------

The last evaluation before the first dose of the study drug was used as baseline for all analyses. Full Mayo scores and Inflammatory Bowel Disease Questionnaire (IBDQ, used under license from McMaster University \[[@CR12]\]) scores were determined at weeks 8, 32, and 52. The Mayo subscores for stool frequency and rectal bleeding were calculated based on entries from patient diaries using the worst diary entry from the 3 days before each study visit for each subscore. Partial Mayo score (Mayo score excluding the endoscopy subscore) was evaluated EOW during the first 8 weeks and monthly thereafter. Efficacy endpoints analyzed included response per full Mayo score (decrease of ≥3 points and ≥30 % from baseline plus a decrease in the rectal bleeding subscore \[RBS\] ≥1 or an absolute RBS of ≤1), remission (full Mayo score ≤2 with no individual subscore \>1), and mucosal healing (endoscopy subscore ≤1) at weeks 8, 32, and 52.

Other efficacy analyses at weeks 8, 32, and 52 included RBS, PGA, and stool frequency indicative of mild disease (score ≤1) and IBDQ response (≥16-point increase from baseline in IBDQ score). In addition, the study evaluated the response per partial Mayo score (decrease of ≥2 points and ≥30 % from baseline plus a decrease in the RBS ≥1 or an absolute RBS of ≤1) from weeks 2 to 8 and rates of steroid-free status and steroid-free remission at week 32 and week 52 in the subset of patients taking corticosteroids at baseline. Subgroup analyses included the proportion of patients with remission at week 8 and at week 52 by baseline concomitant medication use (corticosteroids and immunomodulators), and week 52 efficacy (response, remission, and mucosal healing) in patients who achieved response per full and partial Mayo score at week 8. Other analyses included comparison of remission rates at week 8 using full Mayo scores calculated with different calculation methods for the rectal bleeding and stool frequency subscores (worst vs. mean diary entries and 5 vs. 3 days of diary entries), in order to explore the influence of subscore calculation methodology on efficacy rates. Currently, there is not a standard method for the determination of these subscores in terms of days of diary entries used or the use of mean or worst rank approaches, and different studies have used different approaches. For example, the Western adalimumab studies used the same method that this study used (worst entry of 3 days of diary entries), whereas the golimumab UC development program used the average of 3 days of diary entries \[[@CR13]\].

Pharmacokinetics and immunogenicity {#Sec7}
-----------------------------------

Blood samples for serum adalimumab concentrations were obtained at baseline and weeks 2, 4, 8, 32, and 52. Samples for serum anti-adalimumab antibodies (AAAs) were obtained at baseline and weeks 8, 32, and 52. All blood samples for serum adalimumab and AAA concentrations were obtained before scheduled drug injections. Serum adalimumab concentrations were determined in a central laboratory using a validated enzyme-linked immunosorbent assay method, which was adapted from Weisman et al. \[[@CR14]\] using diluted samples. Serum AAA concentrations were determined using a validated double-antigen immunoassay that detects antibodies directed against epitopes on the entire adalimumab molecule. Similar to other immunoassays available at the time of the performance of the study, the assay detects only free (unbound) AAA. Because the presence of adalimumab in the sample competes with the capture and detector adalimumab for binding to the AAAs, serum samples with an adalimumab concentration \>2 μg/mL were not analyzed for AAAs. Subjects were considered to have AAAs if they had at least one AAA-positive sample.

Safety assessments {#Sec8}
------------------

Patients were monitored continuously for adverse events (AEs), including evaluations every 2 weeks from week 0 to week 52. Other safety parameters (vital signs and clinical laboratory parameters) were ascertained monthly.

Statistical methods {#Sec9}
-------------------

### Sample size {#Sec10}

The target sample size for this study was 85 per arm (total subjects: 225). The sample size was based on expert opinion, taking into consideration the clinical remission rate of adalimumab and infliximab in Western subjects with CD. The sample size was smaller than in Western studies due to the lower prevalence of UC in Japan \[[@CR9]\] compared with Western countries. This trial was designed to allow comparison of directionality of effect with previously published Western studies \[[@CR6], [@CR7]\]. At week 8, the expected remission rates were 30 % in the 160/80 arm, 22 % in the 80/40 arm, and 15 % in the placebo arm. At week 52, the expected rates were 12 % in the combined adalimumab arm (160/80 + 80/40) and 7 % in the placebo arm. The expected probability that week 8 remission would be highest in the 160/80 arm and lowest in the placebo arm was greater than 80 %; likewise, there was also a greater than 80 % expected probability that the week 52 remission rate would be higher in the combined adalimumab arm than in the placebo arm.

### Efficacy analyses {#Sec11}

All statistical analyses were exploratory. The efficacy and safety analyses were conducted on a full analysis set (FAS) that included all patients who received ≥1 dose of the double-blind study drug. Nonresponder imputation, whereby the patient was assumed to not have efficacy, was used for patients with missing data or those who moved to the rescue arm for all efficacy endpoints.

Efficacy analyses for categorical endpoints were performed using the chi-squared test for adalimumab vs. placebo. For week 8 and earlier endpoints, data were analyzed by three induction arms (160/80, 80/40, or placebo). Because both adalimumab induction dosing groups received the same maintenance dose of 40 mg EOW, two arms were analyzed (combined adalimumab or placebo) for time points after week 8.

### Safety analyses {#Sec12}

Adverse events and mean changes from baseline in laboratory variables and vital signs occurring during double-blind therapy were summarized within the FAS. Adverse events in adalimumab-treated patients with response per full Mayo score at week 8 were also evaluated.

### Pharmacokinetic analyses {#Sec13}

Adalimumab concentrations were summarized at each time point using descriptive statistics. The data from all patients randomized to adalimumab who received ≥1 dose of adalimumab and had ≥1 measurable serum adalimumab concentration were included in the pharmacokinetic analyses.

Results {#Sec14}
=======

Disposition and demographics {#Sec15}
----------------------------

A total of 343 patients provided informed consent, and 274 were randomized. Of these 274 patients, 273 (96 in the placebo arm, 87 in the 80/40 arm, and 90 in the 160/80 arm) constituted the FAS (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Patient disposition. *AE* adverse event

The one patient not included in the FAS inadvertently received rescue medication instead of double-blind treatment and was discontinued from the study.

Study participants were predominantly male and representative of a moderately to severely active UC population, with a mean duration of UC of approximately 8 years and a baseline Mayo score of approximately 9 (Table [1](#Tab1){ref-type="table"}). More than 60 % of patients in each arm had pancolitis, with the highest percentage of pancolitis (70 %) occurring in the adalimumab 160/80 arm. The majority of patients were taking UC-related medications at baseline, with ≥90 % receiving aminosalicylic acids, ≥60 % taking steroids, and ≥40 % receiving immunomodulators. The highest rate of baseline steroid use was in the adalimumab 80/40 arm and the highest rate of immunomodulator use was in the placebo arm.Table 1Patient demographics and baseline characteristics (FAS)CharacteristicPlacebo (*N* = 96)ADA 80/40 mg (*N* = 87)ADA 160/80 mg (*N* = 90)Male, *n* (%)70 (72.9)50 (57.5)61 (67.8)Age, mean ± SD (years)41.3 ± 13.644.4 ± 15.042.5 ± 14.6Weight, mean ± SD (kg)60.8 ± 14.158.7 ± 11.160.1 ± 12.3Tobacco, nonsmoker, *n* (%)55 (57.3)53 (60.9)50 (55.6)Alcohol, nondrinker, *n* (%)36 (37.5)45 (51.7)43 (47.8)Duration of UC (years) Mean ± SD7.8 ± 6.68.3 ± 7.77.8 ± 7.1 Range0.6--26.60.8--37.80.4--32.5Site of UC, *n* (%) Pancolitis59 (61.5)54 (62.1)63 (70.0) Descending colon35 (36.5)32 (36.8)27 (30.0) Other^a^2 (2.1)1 (1.1)0Mayo score, mean ± SD8.5 ± 1.68.5 ± 1.48.6 ± 1.4Partial Mayo score, mean ± SD6.1 ± 1.36.0 ± 1.36.2 ± 1.4IBDQ score, mean ± SD^b^148.2 ± 28.9144.9 ± 28.7146.0 ± 31.7C-reactive protein, median (range) (mg/dL)0.34 (0.05--8.72)0.31 (0.05--10.77)0.22 (0.05--6.28)Baseline UC medication, *n* (%) 5-ASAs89 (92.7)84 (96.6)83 (92.2) Immunomodulators (AZA, 6-MP)52 (54.2)38 (43.7)41 (45.6) Systemic corticosteroids58 (60.4)63 (72.4)57 (63.3)Baseline is the last measurement time point before the first dose of study medication in the induction period*ADA* adalimumab, *5-ASA* 5-aminosalicylic acid, *AZA* azathioprine, *FAS* full analysis set, *IBDQ* Inflammatory Bowel Disease Questionnaire, *6-MP* 6-mercaptopurine, *SD* standard deviation, *UC* ulcerative colitis^a^Two patients (distal colitis and appendix/ascending colon/rectal colon/transverse colon) in the placebo arm and one patient (rectal to sigmoidal colon) in the 80/40 mg arm^b^Placebo, *n* = 96; 80/40 arm, *n* = 85; 160/80 arm, *n* = 88

During 52 weeks of treatment, more patients in the placebo arm (66 %) moved to rescue therapy than in the adalimumab 80/40 (57 %) or 160/80 (51 %) arms. The rate of study completion on double-blind therapy was higher in the adalimumab 160/80 arm (40 %) than the placebo (27 %) or 80/40 (33 %) arms (Fig. [1](#Fig1){ref-type="fig"}).

Efficacy {#Sec16}
--------

### Induction therapy {#Sec17}

The rates of early response (per partial Mayo score at weeks 2, 4, and 6, and per full Mayo score at week 8) are shown in Fig. [2](#Fig2){ref-type="fig"}a. Adalimumab 160/80 mg treatment was associated with the highest rates of clinical response at each time point (*P* = 0.044 at week 8 vs. placebo). Week 8 remission and mucosal healing rates by treatment arm are shown in Fig. [2](#Fig2){ref-type="fig"}b. Remission rates were similar between placebo and both adalimumab treatment arms, but adalimumab 160/80 mg was associated with the highest rate of mucosal healing (*P* = 0.045 for 160/80 mg vs placebo). The proportions of patients with improvement in each Mayo subscore (reduction by ≥1) and IBDQ response were greater in the adalimumab arms compared with placebo (Table [2](#Tab2){ref-type="table"}).Fig. 2Response during induction therapy (**a**) and remission and mucosal healing at week 8 (**b**; FAS, NRI). *FAS* full analysis set, *NRI* nonresponder imputation. ^a^Per partial Mayo score. ^b^Per full Mayo score. \**P* = 0.044. ^†^ *P* = 0.045Table 2Other efficacy endpoints (FAS, NRI)Endpoint, *n* (%)^a^Week 8Week 32Week 52Placebo (*N* = 96)ADA 80/40 mg (*N* = 87)ADA 160/80 mg (*N* = 90)Placebo (*N* = 96)ADA 40 mg EOW (*N* = 177)Placebo (*N* = 96)ADA 40 mg EOW (*N* = 177)Rectal bleeding subscore ≤165 (67.7)70 (80.5)\*64 (71.1)27 (28.1)74 (41.8)22 (22.9)59 (33.3)PGA subscore ≤143 (44.8)41 (47.1)55 (61.1)\*27 (28.1)66 (37.3)19 (19.8)57 (32.2)\*Stool frequency subscore ≤131 (32.3)30 (34.5)36 (40.0)20 (20.8)57 (32.2)\*13 (13.5)51 (28.8)\*IBDQ response^b^38 (39.6)42 (48.3)38 (42.2)21 (21.9)55 (31.1)12 (12.5)45 (25.4)^†^Steroid-free^c^NDNDND12 (20.7)35 (29.2)12 (20.7)39 (32.5)Steroid-free remission^c^NDNDND5 (8.6)12 (10.0)4 (6.9)17 (14.2)*ADA* adalimumab, *EOW* every other week, *FAS* full analysis set, *IBDQ* Inflammatory Bowel Disease Questionnaire, *ND* not determined, *NRI* nonresponder imputation, *PGA* physician's global assessment, *UC* ulcerative colitis^a^Unless otherwise noted^b^Response was defined as an increase in IBDQ score of ≥16 points from baseline^c^Percentages calculated based on the number of patients taking steroids at baseline (placebo, *N* = 58; ADA 40 mg EOW, *N* = 120)\* *P* ≤ 0.05, ^†^ *P* ≤ 0.01

### Maintenance therapy {#Sec18}

Maintenance therapy with adalimumab 40 mg EOW was associated with higher rates of response, remission, and mucosal healing at weeks 32 and 52 compared with placebo (Fig. [3](#Fig3){ref-type="fig"}). Rates of remission for the adalimumab-treated patients were greater than placebo at both weeks 32 and 52 (*P* = 0.038 and *P* = 0.001, respectively; Fig. [3](#Fig3){ref-type="fig"}b). The proportion of adalimumab-treated patients with remission increased over time, with the highest rate (23.2 %) observed at week 52 in spite of the use of a nonresponder imputation analysis. Rates of response (Fig. [3](#Fig3){ref-type="fig"}a) and mucosal healing (Fig. [3](#Fig3){ref-type="fig"}c) were sustained compared with placebo over time.Fig. 3Response (**a**), remission (**b**), and mucosal healing (**c**) during maintenance therapy (FAS, NRI). *EOW* every other week, *FAS* full analysis set, *NRI* nonresponder imputation. \**P* = 0.011. ^†^ *P* = 0.021. ^‡^ *P* = 0.038. ^§^ *P* = 0.001. ^‖^ *P* = 0.015

The percentage of patients receiving corticosteroids at baseline who were steroid-free and the percentages who achieved steroid-free remission during the maintenance period are shown in Table [2](#Tab2){ref-type="table"}. Nearly one-third (32.5 %) of adalimumab-treated patients taking steroids at baseline were steroid-free at week 52 compared with 20.7 % of patients taking placebo.

### Adalimumab week 8 responders {#Sec19}

Patients exhibiting response to adalimumab induction therapy at week 8 were more likely to achieve efficacy at week 52 compared with the overall adalimumab-treated population. Among the 82 patients who achieved response per full Mayo score at week 8, 61 % maintained response at week 52, 46 % were in remission, and 57 % had mucosal healing. Similar values were observed when week 8 response was determined using partial Mayo score (*N* = 81): 58 % for response, 44 % for remission, and 54 % for mucosal healing.

### Efficacy by baseline concomitant medications {#Sec20}

At week 8, there was a high rate of remission noted in patients in the placebo arm who were not receiving immunomodulators (22.7 %) and those receiving corticosteroids (17.2 %; Supplementary Table S1). Baseline steroids or immunomodulators had an inconsistent effect in the adalimumab arms, depending on the dose. At week 52, there was a notable negative effect of baseline steroid use on remission rates. Patients in the placebo arm who were not receiving immunomodulators at baseline had a higher rate of remission at week 52 than those who were taking them; the opposite effect was noted in the adalimumab-treated patients.

### Effect of Mayo subscore calculation method on remission rates {#Sec21}

Rates of remission at week 8 for all three arms and the treatment effect sizes (adalimumab rate minus placebo rate) were affected by the method used to assign values at the study visit for Mayo score subscores for stool frequency and rectal bleeding (Supplementary Table S2). The lowest rates of remission and the smallest effect sizes were observed when subscores were based on the worst daily patient diary entries during a 5-day or a 3-day period. Remission rates and effect sizes were greater when the Mayo scores were based on the average of these two subscores from 3 or 5 days of diary entries, with the mean of the 5-day method resulting in the highest overall remission rates and the largest effect sizes.

Pharmacokinetics/immunogenicity {#Sec22}
-------------------------------

Adalimumab trough serum concentrations by randomized group and by remission status at week 8 and week 52 are shown in Table [3](#Tab3){ref-type="table"}. No adalimumab was detected in any samples at week 0. Within each dosing arm, serum concentrations were similar by remission status at week 8. At week 52, patients with remission had slightly higher serum adalimumab concentrations than those who did not achieve remission, with significant overlap by remission status. Overall, 12 of 240 (5.0 %) patients who received adalimumab during the study developed AAAs.Table 3Adalimumab trough serum concentrations during induction and maintenance treatmentTreatmentRemission status at week 8Mean, μg/mL ± SD (Min--Max), *N* ~nmiss~Remission status at week 52Mean, μg/mL ± SD (Min--Max), *N* ~nmiss~WeekWeek2483252ADA 80/40 mgYes (*n* = 12)5.51 ± 2.19 (1.18--8.14), 124.96 ± 2.59 (0.92--8.41), 125.97 ± 2.69 (0.82--10.4), 12Yes (*n* = 23)9.38 ± 5.50 (3.99--24.8), 239.19 ± 3.69 (3.56--16.8), 23No (*n* = 75)6.29 ± 1.68 (3.65--12.1), 755.65 ± 2.30 (0--10.9), 746.19 ± 3.03 (0--12.5), 72No (*n* = 37)^a^7.31 ± 4.46 (0--17.0), 257.77 ± 5.23 (0--16.7), 19ADA 160/80 mgYes (*n* = 9)13.2 ± 3.12 (8.19--17.6), 913.9 ± 2.90 (9.71--17.7), 911.1 ± 3.16 (5.77--16.9), 9Yes (*n* = 18)10.1 ± 3.28 (4.16--16.7), 189.44 ± 3.62 (0.55--16.6), 16No (*n* = 81)^b^13.4 ± 4.58 (3.60--30.4), 8013.3 ± 5.16 (0--31.6), 799.15 ± 5.03 (0--24.7), 77No (*n* = 48)^c^6.63 ± 5.28 (0--18.5), 357.07 ± 5.25 (0--17.4), 33*ADA* adalimumab, *N* ~*nmiss*~ number of nonmissing observations, *SD* standard deviation^a^Twenty-seven patients who entered the rescue arm were excluded^b^One patient was incorrectly rescued at week 0 and excluded from analysis^c^Twenty-four patients who entered the rescue arm were excluded

Safety {#Sec23}
------

The overall safety profile of adalimumab was similar to that observed in other clinical trials, including trials in patients with UC \[[@CR6]--[@CR8]\] and CD \[[@CR10], [@CR15], [@CR16]\], and no new safety signals were observed. Most AEs were nonserious, mild, or moderate in severity, and were considered "not related" or "probably not related" to the study drug by the investigator. During the induction period, the overall rate of AEs was similar in the placebo arm vs. the 80/40 and 160/80 arms (Table [4](#Tab4){ref-type="table"}). Serious AEs and worsening or flare of UC were most common in the placebo arm, and infections and injection site reactions were most common in the adalimumab 160/80 arm. There were three serious infections during the induction period, all of which occurred in the adalimumab 160/80 arm. Exposure-adjusted rates of AEs occurring during 52 weeks of double-blind treatment for patients receiving placebo, patients receiving adalimumab, and patients with response to adalimumab at week 8 per full Mayo score are shown in Table [4](#Tab4){ref-type="table"}. Rates for overall AEs and serious AEs were similar between placebo and adalimumab. Patients receiving adalimumab were more likely to experience AEs considered to be at least possibly drug-related, AEs leading to discontinuation, serious infections, and injection site reactions compared to patients receiving placebo. All injection site reactions were mild, and most were managed without study drug interruption or discontinuation. Patients receiving placebo were more likely to experience worsening or flare of UC. Compared with the overall adalimumab population, patients with response at week 8 were less likely to experience an AE, serious AE, injection site reaction, or flare/worsening of UC.Table 4Overview of adverse events occurring during double-blind therapyAE, *n* (%)Week 8, *n* (%)Week 52, E (E/100 PY)Placebo (*N* = 96)ADA 80/40 mg (*N* = 87)ADA 160/80 mg (*N* = 90)Placebo (*N* = 96) PY = 44.8ADA 40 mg EOW (*N* = 177) PY = 98.2ADA week 8 responders per full Mayo score (*N* = 82) PY = 68.7Any AE45 (46.9)49 (56.3)40 (44.4)273 (609.4)538 (547.9)343 (499.3) At least possibly drug-related10 (10.4)14 (16.1)12 (13.3)34 (75.9)91 (92.7)64 (93.2) Serious7 (7.3)2 (2.3)4 (4.4)14 (31.3)33 (33.6)20 (29.1) Leading to early discontinuation4 (4.2)06 (6.7)6 (13.4)22 (22.4)11 (16.0)AE of interest Infection15 (15.6)11 (12.6)17 (18.9)70 (156.3)134 (136.5)90 (131.0) Serious infection003 (3.3)2 (4.5)8 (8.1)6 (8.7) Malignancy^a^001 (1.1)02 (2.0)1 (1.5) Injection site reaction2 (2.1)5 (5.7)7 (7.8)4 (8.9)20 (20.4)9 (13.1) Opportunistic infection (excluding tuberculosis)^b^001 (1.1)02 (2.0)2 (2.9) Tuberculosis001 (1.1)01 (1.0)0 Hepatic event1 (1.0)01 (1.1)3 (6.7)5 (5.1)3 (4.4) Allergic reaction01 (1.1)02 (4.5)6 (6.1)5 (7.3) Hematologic event1 (1.0)3 (3.4)1 (1.1)4 (8.9)6 (6.1)4 (5.8) UC worsening/flare8 (8.3)2 (2.3)2 (2.2)15 (33.5)18 (18.3)7 (10.2)*ADA* adalimumab, *AE* adverse event, *E* event, *EOW* every other week, *PY* patient-year, *UC* ulcerative colitis^a^One pancreatic carcinoma and one parathyroid tumor, which was determined to be benign but was conservatively classified as a malignancy^b^One *Mycobacterium avium* complex infection and one cytomegalovirus infection

During the entire trial, two malignancies were reported, both of which were considered to be unrelated to the study drug by the investigator. One case of tuberculosis was reported on day 73 (44 days after the last dose of the study drug) in a 65-year-old patient in the adalimumab 160/80 arm receiving prednisone 20 mg/day; this patient had presented with a negative purified protein derivative test (erythema \>10 mm but no induration) and chest X-ray at baseline. The patient was hospitalized on day 81 and died on day 91. There were no cases of lymphoma, melanoma, congestive heart failure, demyelination, or lupus-like syndrome.

Similar to data observed in other clinical studies, the presence of immunogenicity did not have a clinically significant influence on the safety of adalimumab. Through week 52, the overall rate of AEs in the AAA-positive patients (*n* = 5) was 571.4 events per 100 patient-years (compared to 547.9 events/100 patient-years in the overall adalimumab 40 mg EOW group), and all of the AEs reported in these patients were also reported in the patients without immunogenicity (data not shown).

Mean changes from baseline in laboratory variables and vital signs were similar across treatment arms (data not shown). Analyses of laboratory parameters and vital signs did not reveal any clinically relevant safety issues.

Discussion {#Sec24}
==========

The purpose of the present study was to compare the efficacy and safety results of adalimumab for induction and maintenance treatment in Japanese patients with moderately to severely active UC with those of patients from similar studies conducted in Western populations \[[@CR6]--[@CR8]\]. Adalimumab 160/80 mg induction treatment in patients who were unresponsive to corticosteroids and/or immunomodulatory therapy significantly improved the rate of response compared with placebo at week 8, with a rate of response similar to that observed in the pivotal phase III ULTRA 2 trial involving Western patients \[[@CR7]\]. The current study did not demonstrate a greater rate of remission at week 8 with either adalimumab dose compared with placebo, but the adalimumab 160/80 mg induction dosing was associated with significantly greater mucosal healing at week 8 compared with placebo. Maintenance therapy with adalimumab 40 mg EOW was associated with increasing rates of remission over time, with statistical separation compared with placebo observed at weeks 32 and 52. Rates of response and mucosal healing during maintenance treatment were also greater with adalimumab compared with placebo. Maintenance therapy was accompanied by greater rates of mild or normal subscores for RBS, PGA, and stool frequency, and a higher rate of IBDQ response compared with placebo. Additionally, adalimumab therapy was associated with meaningful rates of steroid discontinuation in patients taking steroids at baseline, with approximately 48 % of patients becoming steroid-free at week 52. Greater rates of steroid-free remission were also observed with adalimumab compared with placebo.

Because UC is less common in Japan than in the West, it would have been difficult to enroll a large number of Japanese patients; thus, the current study has a similar study design to that of previously published Western studies \[[@CR6], [@CR7]\] to allow comparison for directionality of effect. Western studies have reported a significant effect of adalimumab on the induction (at week 8, 16.5--18.5 % of patients who received 160/80 mg; *P* \< 0.05 vs placebo) \[[@CR6], [@CR7]\] and maintenance (at week 52, 17.3 % of patients who received 160/80 mg induction followed by 40 mg EOW; *P* \< 0.005 vs placebo) \[[@CR7]\] of remission in patients with moderately to severely active UC who had failed therapy with steroids and/or immunomodulators (including some patients who had failed infliximab in one of the Western studies). Given previous data that demonstrated similar efficacy of adalimumab in Japanese and Western patients with CD \[[@CR10]\], it was expected that the efficacy of adalimumab in patients with UC would be similar to that observed in Western patients. With the exception of week 8 remission, the results in this study were generally consistent with those observed in the Western studies \[[@CR6], [@CR7]\]. In the current study, a high rate of remission was noted in the placebo arm among patients taking steroids at baseline. These findings are consistent with the known short-term effects of steroids to reduce symptoms. It is possible that, unlike in the Western studies, the patients in the Japanese study who were taking steroids at baseline may not have been truly steroid-resistant. This phenomenon was not noted at week 52, which is also consistent with the known lack of long-term efficacy noted with steroid therapy \[[@CR17]\].

Serum adalimumab concentrations at weeks 2 and 4 after induction therapy with adalimumab 160/80 were comparable in Japanese patients with UC (\~13 μg/mL) and in Western patients with UC (\~12 μg/mL) \[[@CR18]\]. During maintenance therapy, mean serum adalimumab concentrations among patients who did not enter the rescue arm were 9.3 μg/mL in patients with remission at week 52 (compared with 10.8 μg/mL in Western patients) and 6.8 μg/mL in patients without remission (compared with 6.2 μg/mL in Western patients) \[[@CR7]\]. As was noted in the Western study \[[@CR7]\], there is substantial overlap in concentrations by remission status at each time point. The immunogenicity rate in this study was comparable with the Western study (5.0 and 5.3 %, respectively) \[[@CR7]\], similar to observations in previous studies in Japanese patients \[[@CR10], [@CR19]\].

Overall, the AE profile of adalimumab was similar to that reported in Western patients with moderately to severely active UC \[[@CR6], [@CR7]\] and trials of adalimumab in CD \[[@CR10], [@CR15], [@CR16]\]. During induction therapy (weeks 0--8), treatment with adalimumab 160/80 mg was associated with an overall rate of AEs similar to that observed with placebo. Maintenance therapy with adalimumab 40 mg EOW was associated with a similar overall rate of AEs and serious AEs compared with placebo; both of these types of events were observed less frequently among patients with response to adalimumab at week 8.

Serious infections, including tuberculosis, were observed in patients treated with adalimumab in this and other studies, and highlight the need for clinicians to carefully weigh the potential benefits and risks of adalimumab in patients when selecting a treatment. The patient who developed tuberculosis in this study had other risk factors for tuberculosis, including increased age \[[@CR20]\] and concomitant high-dose corticosteroid use \[[@CR21]\]. This patient had undergone standard screening for tuberculosis (purified protein derivative skin testing and chest X-ray), consistent with the recommendations in the Japanese prescribing information for adalimumab \[[@CR22]\]. Cases of tuberculosis have been observed in adalimumab-treated patients with negative screening tests \[[@CR22]\], and may represent new-onset infections or false-negative testing, which may be more likely in patients taking concomitant corticosteroids or immunomodulators \[[@CR20]\]. Clinicians initiating adalimumab in patients on combination immunosuppressive therapy or patients with other risk factors for infections should carefully monitor these patients for signs and symptoms, and have a high index for suspicion of infection in patients with symptoms suggestive of tuberculosis (e.g., persistent cough, weight loss, fever).

The decision to continue long-term therapy in patients with UC is generally based on response to induction therapy. This approach is consistent with clinical practice and international expert guidelines \[[@CR23]\]. Therefore, rates of response, remission, and mucosal healing at week 52 were evaluated in patients who achieved response per either full or partial Mayo score at week 8. Consistent with the results noted in the ULTRA 2 Western maintenance study \[[@CR24]\], week 8 response to adalimumab in the current study was associated with greater rates of response, remission, and mucosal healing compared with the overall adalimumab population at week 52. The greater efficacy over time, coupled with a lower rate of overall AEs in week 8 responders relative to the overall adalimumab population, together support the favorable benefit/risk profile of adalimumab maintenance therapy in patients exhibiting an early response to induction therapy.

The study database allowed for comparison of remission rate determinations using different methodologies for capturing stool frequency and rectal bleeding subscores, which are based upon patient daily diary entries. There is no standard method for capturing the values for these subscores at a patient visit, and this may have implications on the rates of remission observed in clinical trials. In this trial and in the Western adalimumab UC studies, the worst daily diary entry over the 3 days prior to the patient visit was used to determine each subscore. Using this method, a patient who recorded stool frequency subscores of 3, 0, and 0 over the 3 days prior to the visit would be assigned a value of 3 for the Mayo stool frequency subscore. Similarly, a patient with subscores of 3, 3, and 3 on 3 consecutive days would also be assigned a score of 3 for this subscore. Based upon the subscore assigned for that study visit, these patients would be considered to be equivalent in terms of stool frequency, even though the degree of their symptoms differs. If the subscores were determined using an average of the 3 days, the first patient would be assigned a stool frequency subscore of 1 and the second patient would receive a score of 3. This example illustrates how the utilization of worst-case methodology in scoring could have a disproportionate influence on efficacy outcomes with active therapy, particularly if the treatment benefits led to improvement, but not complete control of symptoms. In this trial, week 8 remission rates calculated based on patient diary entries for the stool frequency and rectal bleeding subscores were lowest when the worst values of 3 or 5 days were used compared to the use of average daily entries. Additionally, the reduction in remission rates using the worst rank methodology compared to the average was more pronounced in the adalimumab treatment arms than the placebo arm. The greatest remission rates and the largest treatment effect sizes occurred with the use of the average of 5 days of diary entries. We chose to analyze week 8 remission because patients were not able to escape to the rescue arm before that time, and the escape criteria were based upon Mayo scores calculated using the worst rank of 3 days of diary entries, which may have influenced later results. These findings highlight the importance of considering the effect of endpoint determination methodology during clinical trial design and interpretation of clinical trial data.

A limitation of the current study is its relatively small sample size. Additionally, this study did not evaluate the efficacy of adalimumab in Japanese patients who had previously received other biologic therapies such as infliximab.

In conclusion, adalimumab induction therapy with 160/80 mg was superior to placebo in achievement of early response and mucosal healing, and maintenance therapy with 40 mg every other week was associated with maintenance of these effects, as well as achievement of remission at week 32 and 52 in patients with inadequate response to corticosteroids and/or immunosuppressive agents. The similarity of the clinical remission rates after 52 weeks of adalimumab therapy observed in this relatively small study with those observed in large, pivotal clinical trials \[[@CR6], [@CR7]\] of adalimumab in Western populations supports the use of adalimumab in Japanese patients with moderately to severely active UC, particularly in patients who demonstrate response by week 8 to induction therapy.
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